The Latest Breaking News from Beam Therapeutics

A Relative Strength Rating upgrade for Beam Therapeutics shows improving technical performance.

A Relative Strength Rating upgrade for Beam Therapeutics shows improving technical performance.

Beam Therapeutics unveiled BEAM-101 trial data at ASH, showing improved outcomes in sickle cell patients and promising preclinical BEAM-103 results.

A Relative Strength Rating upgrade for Beam Therapeutics shows improving technical performance.

This article delves into three biotech stocks held in Cathie Wood's ARKK ETF that analysts expect to double in value. Investors looking to add exposure to promising biotech opportunities, with a preference for Wood's disruptive approach to investing, may find these stocks particularly compelling.

Beam Therapeutics sees its Relative Strength Rating hit the 80-plus level.

Beam Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Cathie Wood's flagship Ark Innovation ETF ARKK just had its best week ever thanks to Roku, DraftKings, Palantir and other huge winners on big news.

Genetic diseases can have devastating consequences for the people who inherit them. In recent years, scientists have found that there are human genetic diseases that might be treatable, and perhaps even curable, through gene editing. Gene editing is the process by which sections of a person’s DNA are altered. Commonly…